Literature DB >> 20527234

Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978-2005.

D D'alò1, F Stracci, T Cassetti, M Scheibel, C Pascucci, F La Rosa.   

Abstract

This study analyzed the incidence, mortality and survival after cancer of the female breast and reproductive organs in the Umbria region of Italy with the aim of generating hypotheses to explain trends. Mortality data were supplied by ISTAT (1978-1993) and ReNCaM (1994-2005) and incidence (1994-2005) and survival (at 12/31/2007) data by RTUP. Joinpoint regression was applied to evaluate temporal trends of the age-adjusted incidence and mortality rates. Mortality, incidence and relative survival rates were compared with national and international data. The incidence of breast cancer increased up to 2001 and afterwards significantly decreased; mortality rates significantly decreased after 1994. Uterine corpus incidence was practically stable, and decreased over the study period; mortality from all uterine subsites significantly decreased from 1978 onwards. Trends in ovarian cancer incidence and mortality (after 1985) were constant. Trends in occurrence of breast and cervical cancer were linked to population screening of Umbrian women, noting a low compliance by younger females with cervical cancer screening and emphasizing the opportunity of starting breast cancer screening at a younger age. Trends in the incidence of cancer of the uterus and ovary, though unsteady, were probably related to modifications in risk factor exposure. Survival was better for breast and cervical cancers than in the 1978-1982 period and might be due to early diagnosis and progress in therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20527234

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  FoxM1 and β-catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells.

Authors:  Poyil Pratheeshkumar; Sasidharan Padmaja Divya; Sandeep Kumar Parvathareddy; Norah M Alhoshani; Ismail A Al-Badawi; Asma Tulbah; Fouad Al-Dayel; Abdul K Siraj; Khawla S Al-Kuraya
Journal:  Oncotarget       Date:  2017-12-16

2.  Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.

Authors:  David W Chan; Winnie W Y Hui; Patty C H Cai; Michelle X Liu; Mingo M H Yung; Celia S L Mak; Thomas H Y Leung; Karen K L Chan; Hextan Y S Ngan
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.